Streamline Health Solutions Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

false 0001008586 0001008586 2024-09-19 2024-09-19

 

 

 

 

Date of Report (Date of earliest event reported): September 19, 2024

 

(Exact name of registrant as specified in its charter)

 

 

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (888) 997-8732

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Streamline Health Solutions, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”) on September 19, 2024. Proxies for the Special Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Board’s proposals. At the Special Meeting, the Company’s stockholders voted upon two proposals. The proposals are described in detail in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on August 19, 2024.

 

As of the record date for the Special Meeting, there were 63,324,103 shares of the Company's common stock, par value $0.01 per share, outstanding and entitled to vote on each matter presented for vote at the Special Meeting. At the Special Meeting, 51,411,267 shares of common stock, or approximately 81%, of the outstanding shares of common stock, were represented in person or by proxy. A brief description and the final vote results for each proposal follow.

 

 

 

As a result, the proposal was approved.

 

 

 

 

As a result, the proposal was approved.

 

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.